Portal de Periódicos da CAPES

Circulating tumor DNA as a novel tool to shape clinical trial designs with the potential to impact outcomes: a focus on PI3K inhibitors

2017; Elsevier BV; Volume: 28; Issue: 11 Linguagem: Inglês

10.1093/annonc/mdx480

1569-8041

Dalila Sellami, Bharani Dharan, C. Wilke, Sameul Scherer, Samit Hirawat,

Sarcoma Diagnosis and Treatment

Tumor heterogeneity is a major challenge for drug development, and changes in heterogeneity are thought to contribute to anticancer treatment resistance. However, the standard diagnostic approach in clinical trials relies on analysis of a single (usually archival) sample from the primary tumor [1]. This provides limited characterization of a single tumor at initial diagnosis that is not necessarily representative of current disease status [1]. Recent studies have also highlighted challenges with intratumoral heterogeneity in advanced cancers [2, 3].